Actively Recruiting
Phase I Study of Allogeneic CAR-T Cell Therapy CT0890B for Adults with NKG2DL-Positive Relapsed or Refractory Acute Myeloid Leukemia
Led by Peking University People's Hospital · Updated on 2026-06-01
27
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, effectiveness, and behavior of CT0890B, an allogeneic CAR-T cell therapy, in patients with relapsed or refractory acute myeloid leukemia AML who have NKG2D ligand-positive disease. This Phase 1, open-label, dose-escalation study involves 12 to 27 participants and aims to understand how this treatment works in patients with this challenging form of leukemia. Participants receive a conditioning regimen with venetoclax, cytarabine, cyclophosphamide, and fludarabine over several days before receiving an infusion of CT0890B CAR-T cells at one of four dose levels. The study design follows an i33 dose-escalation approach to determine the best dose. The treatment period includes careful monitoring for adverse events and dose-limiting toxicities up to 28 days after infusion. During the 12 months following infusion, participants will be closely monitored through clinical assessments, laboratory tests, and pharmacokinetic studies to evaluate responses such as remission rates, survival, and minimal residual disease status. Safety will be tracked by observing adverse events and toxicities. Researchers will also assess how long the CAR-T cells persist in the body and their expansion over time, with total participation lasting up to one year after treatment.
CONDITIONS
Brief Title
Allogeneic CAR-T(CT0890B) in NKG2DL+ R/R AML
Research Team
X
Xiangyu Zhao, M.D,Ph.D
M
Meng Lv, M.D., Ph.D
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here